The stock of Fulcrum Therapeutics Inc (FULC) has seen a 25.33% increase in the past week, with a 10.77% gain in the past month, and a -17.34% decrease in the past quarter. The volatility ratio for the week is 7.45%, and the volatility levels for the past 30 days are at 8.23% for FULC. The simple moving average for the past 20 days is 13.48% for FULC’s stock, with a -31.56% simple moving average for the past 200 days.
Is It Worth Investing in Fulcrum Therapeutics Inc (NASDAQ: FULC) Right Now?
FULC has 36-month beta value of 2.25. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for FULC is 47.85M, and currently, short sellers hold a 7.80% ratio of that float. The average trading volume of FULC on April 18, 2025 was 405.05K shares.
FULC) stock’s latest price update
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) has jumped by 7.52 compared to previous close of 3.06. Despite this, the company has seen a gain of 25.33% in its stock price over the last five trading days. globenewswire.com reported 2025-04-11 that CAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with H.C. Wainwright repeating the rating for FULC by listing it as a “Neutral.” The predicted price for FULC in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on September 13, 2024 of the previous year 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to FULC, setting the target price at $4 in the report published on September 12th of the previous year.
FULC Trading at 2.97% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.52% of loss for the given period.
Volatility was left at 8.23%, however, over the last 30 days, the volatility rate increased by 7.45%, as shares surge +8.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.86% lower at present.
During the last 5 trading sessions, FULC rose by +25.33%, which changed the moving average for the period of 200-days by -47.86% in comparison to the 20-day moving average, which settled at $2.90. In addition, Fulcrum Therapeutics Inc saw -30.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FULC starting from Tourangeau Greg, who sale 236 shares at the price of $7.76 back on May 07 ’24. After this action, Tourangeau Greg now owns 11,571 shares of Fulcrum Therapeutics Inc, valued at $1,831 using the latest closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -0.27 for the present operating margin
- 0.78 for the gross margin
The net margin for Fulcrum Therapeutics Inc stands at -0.12. The total capital return value is set at -0.09. Equity return is now at value -4.07, with -3.75 for asset returns.
Based on Fulcrum Therapeutics Inc (FULC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26.
Currently, EBITDA for the company is -18.24 million with net debt to EBITDA at 3.24. When we switch over and look at the enterprise to sales, we see a ratio of 1.6. The receivables turnover for the company is 23.94for trailing twelve months and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.63.
Conclusion
To put it simply, Fulcrum Therapeutics Inc (FULC) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
